AI-guided structural modeling and proteomics identified molecular glues that degrade VAV1, a potential target in blood cancers and autoimmune diseases.
Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
Consortium members are expected to have access to the dataset by early 2027, and there are plans to add more complex antibody ...
The findings by scientists at NYU Abu Dhabi provide new insight into how cells respond when cancer-causing genes are ...
Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to ...
Researchers at the Nano Life Science Institute at Kanazawa University in Japan say they have directly visualized how enzymes ...
The finding may make it possible to launch saRNA vaccines faster for use in gene therapy, cancer immunotherapy, and protein replacement.
Nektar Therapeutics won its legal dispute with Eli Lilly over rezpegaldesleukin, but the court victory failed to deliver a ...
Thar Process, based in Pittsburgh, PA, a specialist in supercritical CO 2 extraction and purification technology (SFE and SFC), partnered with ExtrateX, a French expert firm in supercritical fluid ...
The results of a study by researchers at Texas Children’s Duncan Neurological Research Institute (Duncan NRI), at Baylor ...
Their ability to destroy bacterial cells has made bacteriophages promising candidates for addressing antimicrobial resistance and reducing reliance on agrochemicals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results